The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,000
Tashkin, D. P., Rennard, S. I., Hays, J. T., Lawrence, D., Márton, J., & Lee, T. C. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.04.016 · Cited by 58
Multidisciplinary Care of the Patient with Chronic Obstructive Pulmonary Disease
Kuzma, A. M., Meli, Y. M., Meldrum, C., Jellen, P. A., Butler-Lebair, M., Koczen-Doyle, D., Rising, P., Stavrolakes, K., & Brogan, F. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200708-125et · Cited by 59
Pachas, G. N., Cather, C., Pratt, S. I., Hoeppner, B. B., Nino, J., Carlini, S. V., Achtyes, E. D., Lando, H. A., Mueser, K. T., Rigotti, N. A., et al. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.663675 · Cited by 58
Pharmacotherapy of Addictive Disorders
Ross, S., & Peselow, E. D. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a91655 · Cited by 57
Nicotine Dependence: Biology, Behavior, and Treatment
Ray, R., Schnoll, R. A., & Lerman, C. E. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.041707.160511 · Cited by 59
Therapeutic vaccines against tobacco addiction
Fahim, R. E. F., Kessler, P., & Kalnik, M. W. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.13 · Cited by 57
Adherence to Varenicline and Associated Smoking Cessation in a Community-Based Patient Setting
Liberman, J. N., Lichtenfeld, M. J., Galaznik, A., Mastey, V., Harnett, J., Zou, K. H., Leader, J. B., & Kirchner, H. L. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.125 · Cited by 57
Emerging issues in smoking among adolescent and adult cancer survivors
Klosky, J. L., Tyc, V. L., Garces‐Webb, D. M., Buscemi, J., Klesges, R. C., & Hudson, M. M. (2007) · Cancer · doi:10.1002/cncr.23061 · Cited by 57
Baker, T. B., Piper, M. E., Smith, S. S., Bolt, D. M., Stein, J. H., & Fiore, M. C. (2021) · JAMA · doi:10.1001/jama.2021.15333 · Cited by 58
Pharmacotherapy of smoking cessation
Jiloha, R. C. (2014) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.124726 · Cited by 60
Nicotinic receptor-based therapeutics and candidates for smoking cessation
Dwoskin, L. P., Smith, A. M., Wooters, T. E., Zhang, Z., Crooks, P. A., & Bardo, M. T. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.002 · Cited by 57
Bolliger, C. T., Issa, J. S., Posadas-Valay, R., Safwat, T., Abreu, P. C., Correia, E. A., Park, P. W., & Chopra, P. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.013 · Cited by 55
Varenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression
Pumariega, A. J., Nelson, R., & Rotenberg, L. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900016746 · Cited by 55
Chi, Y., & Jaff, M. R. (2008) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.21401 · Cited by 55
Harrison-Woolrych, M., & Ashton, J. (2011) · Drug Safety · doi:10.2165/11594450-000000000-00000 · Cited by 54
Non‐pharmacological treatments for COPD
Mulhall, P., & Criner, G. J. (2016) · Respirology · doi:10.1111/resp.12782 · Cited by 56
Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer?
Ebbert, J. O., Hays, J. T., & Hurt, R. D. (2010) · Drugs · doi:10.2165/11536100-000000000-00000 · Cited by 53
Zaveri, N. T., Jiang, F., Olsen, C. M., Polgar, W. E., & Toll, L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1006148 · Cited by 53
Gray, K. M., Carpenter, M. J., Lewis, A. L., Klintworth, E., & Upadhyaya, H. P. (2011) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr130 · Cited by 53
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.019 · Cited by 53
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
Halperin, A. C., McAfee, T. A., Jack, L. M., Catz, S. L., McClure, J. B., Deprey, T. M., Richards, J. A., Zbikowski, S. M., & Swan, G. E. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.09.001 · Cited by 53
Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients
Stein, J. H., Hadigan, C. M., Brown, T. T., CHADWICK, E. G., Feinberg, J., Friis‐Møller, N., Ganesan, A., Glesby, M. J., Hardy, D., Kaplan, R. C., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.189628 · Cited by 54
Pharmacotherapy for Smoking Cessation
Raupach, T., & van Schayck, O. C. P. (2011) · CNS Drugs · doi:10.2165/11590620-000000000-00000 · Cited by 54
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration
George, O., Lloyd, A., Carroll, F. I., Damaj, M. I., & Koob, G. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2024-3 · Cited by 54
Gonzales, D. H., Hájek, P., Pliamm, L., Nackaerts, K., Tseng, L.-J., McRae, T. D., & Treadow, J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.124 · Cited by 52
Self-citationRecent advances with 5‐HT3 modulators for neuropsychiatric and gastrointestinal disorders
Jůza, R., Vlček, P., Mezeiová, E., Musílek, K., Soukup, O., & Korábečný, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21666 · Cited by 55
Masaki, K., Tateno, H., Kameyama, N., Morino, E., Watanabe, R., Sekine, K., Ono, T., Satake, K., Suzuki, S., Nomura, A., et al. (2019) · JMIR mHealth and uHealth · doi:10.2196/12694 · Cited by 51
Bader, P., McDonald, P., & Selby, P. L. (2008) · Tobacco Control · doi:10.1136/tc.2008.025635 · Cited by 51
Lorcaserin for Smoking Cessation and Associated Weight Gain: A Randomized 12-Week Clinical Trial
Shanahan, W. R., Rose, J. E., Glicklich, A., Stubbe, S., & Sanchez‐Kam, M. (2016) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntw301 · Cited by 51
Achieving Smoking Cessation Among Persons with Opioid Use Disorder
Vlad, C., Arnsten, J. H., & Nahvi, S. (2020) · CNS Drugs · doi:10.1007/s40263-020-00701-z · Cited by 51
Effects of Smoking and Smoking Cessation on the Intestinal Microbiota
Sublette, M. G., Cross, T.-W., Korcarz, C. E., Hansen, K. M., Murga-Garrido, S. M., Hazen, S. L., Wang, Z., Oguss, M. K., Rey, F. E., & Stein, J. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092963 · Cited by 53
Adapting Smoking Cessation Treatment According to Initial Response to Precessation Nicotine Patch
Rose, J. E., & Behm, F. M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12070919 · Cited by 51
Multiple brain pathways and receptors underlying tobacco addiction
Rose, J. E. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.039 · Cited by 51
Garza, D., Murphy, M. F., Tseng, L., Riordan, H., & Chatterjee, A. K. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.005 · Cited by 50
A 51-Year-Old Woman With Bipolar Disorder Who Wants to Quit Smoking
Schroeder, S. A. (2009) · JAMA · doi:10.1001/jama.2008.982 · Cited by 51
Nahvi, S., Ning, Y. M., Segal, K. S., Richter, K. P., & Arnsten, J. H. (2014) · Addiction · doi:10.1111/add.12631 · Cited by 50
South African tobacco smoking cessation clinical practice guideline
van Zyl-Smit, R. N., Allwood, B., Stickells, D., Symons, G., Abdool-Gaffar, S., Murphy, K., Lalloo, U., Vanker, A., Dheda, K. U. J., & Richards, G. A. (2013) · South African Medical Journal · doi:10.7196/samj.7484 · Cited by 51
Keating, G. M., & Siddiqui, M. A. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620110-00007 · Cited by 50
Quik, M., Campos, C., & Grady, S. R. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.027 · Cited by 50
Nahvi, S., Wu, B. B., Richter, K. P., Bernstein, S. L., & Arnsten, J. H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.026 · Cited by 48
Jeong, S. H., Newcombe, D. A. L., Sheridan, J. L., & Tingle, M. D. (2014) · Drug Testing and Analysis · doi:10.1002/dta.1707 · Cited by 48
Foulds, J., Russ, C., Yu, C.-R., Zou, K. H., Galaznik, A., Franzon, M., Berg, A. S., & Hughes, J. R. (2013) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntt066 · Cited by 51
Hurt, R. T., Ebbert, J. O., Croghan, I. T., Schroeder, D. R., Hurt, R. D., & Hays, J. T. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.11.017 · Cited by 48
Aripiprazole, alcohol and substance abuse: a review.
Brunetti, M., Tizio, L. D., Dezi, S., Pozzi, G., Grandinetti, P., & Martinotti, G. (2012) · PubMed · Cited by 48
Covey, L. S., Glassman, A. H., Jiang, H., Fried, J., Masmela, J. R., LoDuca, C., Petkova, E., & Rodriguez, K. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.01887.x · Cited by 48
Smoking outcome by psychiatric history after behavioral and varenicline treatment
McClure, J. B., Swan, G. E., Catz, S. L., Jack, L. M., Javitz, H. S., McAfee, T. A., Deprey, M., Richards, J. A., & Zbikowski, S. M. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.03.007 · Cited by 47
Effects of smoking cessation on central blood pressure and arterial stiffness
Takami, T., & Saito (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s25798 · Cited by 47
Gariti, P., Lynch, K. G., Alterman, A. I., Kampman, K., Xie, H., & Varillo, K. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.01.006 · Cited by 48
Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder
Sutherland, M. T., & Stein, E. A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.002 · Cited by 50
Ashare, R. L., Thompson, M., Serrano, K., Leone, F. T., Metzger, D. S., Frank, I., Gross, R., Hole, A. V., Mounzer, K., Collman, R. G., et al. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.03.011 · Cited by 47
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46
Combination Therapies for Smoking Cessation
Windle, S. B., Filion, K. B., Mancini, J. G., Adye-White, L., Joseph, L., Gore, G. C., Habib, B., Grad, R., Pilote, L., & Eisenberg, M. J. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.07.011 · Cited by 46
Ray, L. A., Courtney, K. E., Ghahremani, D. G., Miotto, K. A., Brody, A. L., & London, E. D. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3519-0 · Cited by 46
Cross-Validation of a New Procedure for Early Screening of Smoking Cessation Medications in Humans
Perkins, K. A., Lerman, C. E., Fonte, C. A., Mercincavage, M., Stitzer, M. L., Chengappa, K. N. R., & Jain, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.65 · Cited by 46
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats
Liu, X., Palmatier, M. I., Caggiula, A. R., Sved, A. F., Donny, E. C., Gharib, M. A., & Booth, S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1335-0 · Cited by 46
Smoking cessation: How compelling is the evidence? A review
Tønnesen, P. (2009) · Health Policy · doi:10.1016/s0168-8510(09)70004-1 · Cited by 46
Araujo, L. H., Horn, L., Merritt, R. E., Shilo, K., Xu‐Welliver, M., & Carbone, D. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00069-4 · Cited by 47
Caponnetto, P., Campagna, D., Ahluwalia, J. S., Russell, C., Maglia, M. G., Riela, P. M., Longo, F., Busà, B., & Polosa, R. (2023) · BMC Medicine · doi:10.1186/s12916-023-02919-2 · Cited by 50
Meyer, T. E., Taylor, L. G., Xie, S., Graham, D. J., Mosholder, A. D., Williams, J. R., Moeny, D. G., Ouellet‐Hellstrom, R., & Coster, T. S. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.04024.x · Cited by 45
Assessing preferences for improved smoking cessation medications: a discrete choice experiment
Marti, J. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0333-z · Cited by 47
Goulart, D., Engroff, P., Ely, L. S., Sgnaolin, V., dos Santos, E. F., Terra, N. L., & Carli, G. A. D. (2010) · Revista Brasileira de Geriatria e Gerontologia · doi:10.1590/s1809-98232010000200015 · Cited by 47
Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence
Fowler, C. D., Turner, J. R., & Damaj, M. I. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_252 · Cited by 50
Hawk, L. W., Ashare, R. L., Lohnes, S. F., Schlienz, N. J., Rhodes, J. D., Tiffany, S. T., Gass, J. C., Cummings, K. M., & Mahoney, M. C. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.317 · Cited by 46
Tobacco dependence in surgical patients
Warner, D. O. (2007) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3280c60c3b · Cited by 45
Oral Varenicline for Smoking Cessation
Zierler-Brown, S., & Kyle, J. A. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h310 · Cited by 45
de Oliveira, C., Cho, E., Kavelaars, R., Jamieson, M., Bao, B., & Rehm, J. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30145-0 · Cited by 44
Tonstad, S., & Lawrence, D. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12543 · Cited by 44
Multivariate framework of the Brief Questionnaire of Smoking Urges
Cappelleri, J. C., Bushmakin, A. G., Baker, C. L., Merikle, E. P., Olufade, A. O., & Gilbert, D. G. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.04.002 · Cited by 45
Gould, R. W., Garg, P., Garg, S., & Nader, M. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.08.004 · Cited by 45
Reus, V. I., & Smith, B. J. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01885.x · Cited by 44
Cardiovascular Safety of Varenicline
Ware, J. H., Vetrovec, G. W., Miller, A. B., Tosh, A. V., Gaffney, M., Yunis, C., Arteaga, C., & BORER, J. S. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828d455b · Cited by 44
Peripheral Arterial Disease in the Elderly
Aronow, H. D. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00002 · Cited by 45
The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/104105 · Cited by 43
Annemans, L., Nackaerts, K., Bartsch, P., Prignot, J., & Marbaix, S. (2009) · Clinical Drug Investigation · doi:10.2165/11317730-000000000-00000 · Cited by 43
Helping patients to reduce tobacco consumption in oncology: a narrative review
Lucchiari, C., Masiero, M. A., Botturi, A., & Pravettoni, G. (2016) · SpringerPlus · doi:10.1186/s40064-016-2798-9 · Cited by 43
Schuit, E., Panagiotou, O. A., Munafo, M. R., Bennett, D., Bergen, A. W., & David, S. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011823.pub2 · Cited by 45
RetractedSmoking cessation: the potential role of risk assessment tools as motivational triggers
Young, R. P., Hopkins, R. J., Smith, M., & Hogarth, D. K. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2009.084947 · Cited by 44
An Employer-Based Cost-Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation
Jackson, K. C., Nahoopii, R., Said, Q., Dirani, R. D., & Brixner, D. I. (2007) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3180459ff2 · Cited by 43
Handling relapse in smoking cessation: strategies and recommendations
Caponnetto, P., Keller, E., Bruno, C. M., & Polosa, R. (2012) · Internal and Emergency Medicine · doi:10.1007/s11739-012-0864-z · Cited by 43
Smoking Use and Cessation Among People with Serious Mental Illness.
Annamalai, A., Singh, N., & O’Malley, S. S. (2015) · PubMed Central · Cited by 42
Emerging drugs for the treatment of tobacco dependence: 2014 update
Elrashidi, M. Y., & Ebbert, J. O. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.899580 · Cited by 43
Tyndale, R. F., Zhu, A. Z. X., George, T. P., Cinciripini, P. M., Hawk, L. W., Schnoll, R. A., Swan, G. E., Benowitz, N. L., Heitjan, D. F., & Lerman, C. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128109 · Cited by 43
Exercise to Enhance Smoking Cessation: the Getting Physical on Cigarette Randomized Control Trial
Harry Prapavessis, A., Jesus, S. D., Fitzgeorge, L., Faulkner, G., Maddison, R., & Batten, S. (2016) · Annals of Behavioral Medicine · doi:10.1007/s12160-015-9761-9 · Cited by 42
Ebbert, J. O., Burke, M. V., & Hays, J. T. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s83469 · Cited by 44
Development and Validation of the Questionnaire of Vaping Craving
Dowd, A. N., Motschman, C. A., & Tiffany, S. T. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty046 · Cited by 42
Efficacy and Safety of Varenicline for Adolescent Smoking Cessation
Gray, K. M., Baker, N. L., McClure, E. A., Tomko, R. L., Squeglia, L. M., Saladin, M. E., & Carpenter, M. J. (2019) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2019.3553 · Cited by 42
Adverse Drug Reactions in Patients with Cardiovascular Disease
Faulx, M. D., & Francis, G. S. (2008) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2008.08.002 · Cited by 42
Varenicline for Smoking Cessation
Klesges, R. C., Johnson, K., & Somes, G. W. (2006) · JAMA · doi:10.1001/jama.296.1.94 · Cited by 42
Sleep Disturbance During Smoking Cessation: Withdrawal or Side Effect of Treatment?
Ashare, R. L., Lerman, C., Tyndale, R. F., Hawk, L. W., George, T. P., Cinciripini, P., & Schnoll, R. A. (2017) · Journal of Smoking Cessation · doi:10.1017/jsc.2016.11 · Cited by 42
Changes in health-related quality of life with smoking cessation treatment
Hays, J. T., Croghan, I. T., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2010) · European Journal of Public Health · doi:10.1093/eurpub/ckq137 · Cited by 41
Pharmacogenetics of smoking cessation therapy
Kortmann, G. L., Dobler, C. J., Bizarro, L., & Bau, C. H. D. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30978 · Cited by 41
Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.
Ashare, R. L., & McKee, S. A. (2011) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0025594 · Cited by 41
Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial
Tanoue, L. T. (2008) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70599-1 · Cited by 41
Wong, J., Abrishami, A., Riazi, S., Siddiqui, N. T., You-Ten, E., Korman, J., Islam, S., Chen, X., Andrawes, M., Selby, P. L., et al. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001894 · Cited by 41
Varenicline: The newest agent for smoking cessation
Potts, L. A., & Garwood, C. L. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060428 · Cited by 41
What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?
Oncken, C. A., & Kranzler, H. R. (2009) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntp136 · Cited by 41
Bolin, K., Mörk, A., Willers, S., & Lindgren, B. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.12.018 · Cited by 41
Recommendations for the Use of Pharmacological Smoking Cessation Strategies in Pregnant Women
Coleman, T. J. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00003 · Cited by 41
Larzelere, M., & Williams, D. E. (2005) · BDJ · doi:10.1038/sj.bdj.4812328 · Cited by 41
A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder
Wu, B. S., Weinberger, A. H., Mancuso, E., Wing, V. C., Haji-Khamneh, B., Levinson, A. J., & George, T. P. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.671067 · Cited by 40
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
